Randomized Trial Comparing High-Dose Targeted Radiation Plus Standard Chemotherapy and Immunotherapy Versus Standard Treatment Alone for Locally Advanced Inoperable Non-Small Cell Lung Cancer
Led by NRG Oncology · Updated on 2026-08-17
474
Participants Needed
477
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the addition of stereotactic body radiation therapy SBRT to the usual treatment for patients with locally advanced, inoperable non-small cell lung cancer that has spread to nearby tissue or lymph nodes. This phase III trial compares the effect of SBRT combined with conventional image guided radiation therapy IGRT, chemotherapy, and subsequent immunotherapy or targeted therapy to the usual treatment alone. The goal is to see if adding SBRT improves overall survival and progression-free survival.
Participants are randomly assigned to one of two groups. Arm I receives conventional IGRT with chemotherapy regimens including paclitaxel, carboplatin, pemetrexed, cisplatin, or etoposide during radiotherapy, followed by consolidation immunotherapy with durvalumab or targeted therapy with osimertinib. Arm II receives SBRT to the primary tumor plus conventional IGRT to nodal metastases along with the same chemotherapy and consolidation treatments. Imaging with CT or PETCT scans is used during follow-up.
During the study, participants undergo regular assessments including scans and pulmonary function tests at baseline and at 6 and 12 months after radiation therapy. Researchers also collect patient-reported outcomes and monitor quality of life, adverse events, and changes in lung function over time. Biospecimens and advanced imaging data are collected for further analysis. Participants are followed every 3 months for the first year, then every 6 months for years 2 and 3, and yearly thereafter, for up to 13 years total.
CONDITIONS
Brief Title
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
High-dose Stereotactic Radiation added to Chemoradiation & Immunotherapy
Standard Chemoradiation plus Immunotherapy
What it is
A treatment approach where a short course of high-dose, targeted stereotactic body radiation therapy (SBRT) is given to the primary lung tumor, followed by standard image-guided chemoradiation (with platinum-based chemotherapy) and immunotherapy (durvalumab or similar).
Standard treatment consisting of image-guided chemoradiation (with platinum-based chemotherapy) followed by immunotherapy consolidation for eligible patients.
Role in the trial
Investigational strategy tested for improved survival and disease control.
Serves as the active comparator by reflecting established standard of care.
Primary use
Aims to improve outcomes by delivering higher local radiation dose to the tumor before standard chemoradiation and immunotherapy in inoperable, node-positive locally advanced NSCLC.
Standard definitive treatment for inoperable, locally advanced NSCLC designed to control disease and prolong survival.
How it is given or performed
Participants receive 3-8 fractions of SBRT to the lung tumor, then undergo daily image-guided chemoradiation with platinum doublet chemotherapy, followed by immunotherapy consolidation.
Participants undergo daily image-guided radiation with concurrent platinum doublet chemotherapy and, after completion, receive immunotherapy consolidation.
Evidence status
Currently under clinical investigation; published studies have explored this approach in early or selected advanced disease but it is not yet guideline-endorsed for all eligible patients.
Established efficacy with improved overall and progression-free survival over prior approaches is supported by multiple randomized studies and guidelines.
Important limitations
Safety profile and long-term effectiveness for adding SBRT to chemoradiation and immunotherapy in stage III patients are not yet established. Most evidence is from ongoing or early-phase trials in selected populations.
Not all patients tolerate combined chemoradiation or immunotherapy. Distant and local recurrence still occur, and outcomes can be limited by comorbid illness.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Diagnosed with non-operable stage IIB or III node-positive non-small cell lung cancer with known PD-L1 status
Presence of a primary tumor and at least one affected lymph node
Up to 4 cycles of prior systemic therapy for current cancer allowed
Patients refusing surgery or medically inoperable are eligible
Separate tumor nodules in the same lobe are eligible
Clinically appropriate for curative combined therapy based on exams and imaging
No distant metastases on PET/CT within 60 days
Primary tumor size 7 cm or less
Age 18 years or older
ECOG performance status between 0 and 2
Adequate blood counts and kidney function for treatment
Non-malignant pleural effusion allowed if confirmed by tests
Eligible for consolidation immunotherapy, including those with certain mutations
Prior or concurrent malignancies allowed if not interfering
Negative pregnancy test within 14 days for those of childbearing potential
Provided informed consent and authorization for health information release
You will not qualify if you...
Prior radiation therapy to the current cancer site or overlapping regions affecting treatment
No identifiable primary tumor or pathologically enlarged lymph node
Centrally located tumor too close to involved nodes causing overlapping radiation fields
Pregnant or unwilling to stop nursing
Childbearing potential participants unwilling to use effective contraception during and after treatment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Initial exams and imaging scans before starting treatment
Treatment
Duration - Up to 1 year or until disease progression or unacceptable toxicity
Participants receive assigned radiation therapy (either conventional IGRT alone or combined with SBRT), chemotherapy during radiation, and consolidation immunotherapy or targeted therapy afterwards.
Weekly chemotherapy during radiation and regular immunotherapy infusions every 2 or 4 weeks
Follow-up
Duration - Up to 13 years
Participants undergo regular CT or PET/CT scans and pulmonary function tests to monitor cancer status, lung function, quality of life, and side effects.
Every 3 months for the first year, every 6 months for years 2-3, then yearly thereafter
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating a Shared Decision-Making Communication Tool Versus Standard Care
for Treatment Choices in Non-Small Cell Lung Cancer
A Randomized Controlled Trial
Phase II Study of Canakinumab to Prevent Lung Cancer in Patients with High-Risk Pulmonary Nodules
Assessment of Heart Injury and Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Personalized Chemoradiation Therapy
Phase I Study of Carfilzomib and Sotorasib for Treating KRAS G12C Mutated Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2 Study of Devimistat with Hydroxychloroquine and 5-Fluorouracil or Gemcitabine
for Advanced Chemotherapy-Resistant Solid Tumors Including Colorectal, Pancreatic, and Others
Phase 2 Study of Defactinib and Avutometinib Combined with Nivolumab for Treating Advanced LKB1-Mutant Lung Adenocarcinoma Not Responding to Anti-PD1 Therapy
Phase II Trial of Diclofenac with Single Agent Immunotherapy for Treating Metastatic Non-Small Cell Lung Cancer with Early Progression Signs
Supportive Dyadic Yoga and Education Interventions to Improve Physical Performance and Quality of Life in Patients With Stage I-IV Non-Small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
Monitoring T Cell Responses to Improve Anti-PD-1 Therapy in Melanoma, Lung, and Other Advanced Cancers
Geriatric Assessment to Improve Treatment and Quality of Life in Older Adults with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Chemotherapy and Radiation
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
John H Heinzerling, Kathryn F Mileham, Myra M Robinson...